Affymax, Inc. (Nasdaq: $AFFY) A Big Spike, Should We Expect More Gains Ahead?
January 11th, 2011 | by Jaxon Hewlett |Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. Affymax, Inc. has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide. The company was founded in 2001 and is based in Palo Alto, California.
Similar Posts:
- OXiGENE, Inc. (NASDAQ: $OXGN) A Traders Trap Or A Serious Breakout About To Occur?
- Cell Therapeutics, Inc. (NASDAQ: $CTIC) CTIC Is Erupting Like A Volcano!?
- Avanir Pharmaceuticals, Inc (NASDAQ: $AVNR) AVNR Is Trying To Breakout Again! Will It Succeed This Time?
- Radient Pharmaceuticals (AMEX: $RPC) On Breakout Mode!
- Intellipharmaceutics International (Nasdaq: $IPCI) Big Mover Should Continue It’s Ascent!
